Neuroendocrine tumors: An overview

Pathology Case Reviews

Volumn 11, Issue 6, 2006, Pages 229-234

  DeLellis, Ronald A ^a   Osamura, Robert Y ^b  

^a RHODE ISLAND HOSPITAL   (United States)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atypical carcinoid; Carcinoid; Chromogranin; Small cell carcinoma; Somatostatin receptors

Indexed keywords

CHROMOGRANIN; CYTOKERATIN; SOMATOSTATIN RECEPTOR; SYNAPTOPHYSIN;

CARCINOID; ELECTRON MICROSCOPY; HUMAN; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PRIORITY JOURNAL; REVIEW; SECRETORY GRANULE; SMALL CELL CARCINOMA; TUMOR CLASSIFICATION; TUMOR DIAGNOSIS;

EID: 33845459541     PISSN: 10829784     EISSN: 15334015     Source Type: Journal    
DOI: 10.1097/01.pcr.0000251144.72627.91     Document Type: Review

References (61)

1. Heidenhain R. Untersuchungen uber den Bau der Labdrusen. Arch Milrosk Ant Entw Mech. 1870;6:387-406.
2. Kulchitsky N. Zur Frage uber den Bau Der Darmkanals. Arch Microsk Anat. 1897;49:70-81.
3. Masson P. La glande endocrine de l'intestin chez l'homme. CR Acad Sci Paris. 1914;158:59-61.
4. Hamperl H. Was sind argentaffine Zellen? Virchows Arch. 1932;286:811-833.
5. Feyrter F. Uber Diffuse Endokrine Epitheliale Organe. Leipzig, Germany: JA Barth; 1938.
6. Froelich F. Die "Helle Zelle" der Bronchialschleimhaut und ihre Beziehungen zum Problem der Chemoreceptoren. Frankfurt Z Pathol. 1949;60:517-559.
7. Pearse AGE. The APUD cell concept and its implications in pathology. Pathol Annu. 1974;9:27-41.
8. Pearse AGE. The diffuse neuroendocrine system and the APUD concept: related "endocrine" peptides in brain, intestine, pituitary, placenta, and anuran cutaneous glands. Med Biol. 1977;55:115-125.
9. DeLellis RA. The neuroendocrine system and its tumors: an overview. Am J Clin Pathol. 2001;115(suppl):S5-S16.
10. Le Douarin N, Fontaine-Perus J. Embryonic origin of polypeptide hormone producing cells. In: Gratzl M, Langley K, eds. Markers for Neural and Endocrine Cells: Molecular and Cell Biology, Diagnostic Applications. Weinheim, Germany: VCH; 1991:3-22.
11. Oberndorfer S. Karzinoide Tumoren des Dunndarms. Frankf Z Pathol. 1907;1426-432.
12. Bensch KG, Corrin B, Pariente R, et al. Oat cell carcinoma of the lung: its origin and relationship to bronchial carcinoid. Cancer. 1968;22:1163-1172.
13. Arrigoni MG, Woolner LB, Bernatz PE. Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972;64:413-421.
14. Williams ED. Histological Typing of Tumors of the Endocrine System. Berlin, Germany: Springer-Verlag; 1980.
15. Gould VE, Linnoila I, Memoli VA, et al. Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias and neoplasms. Lab Invest. 1983;49:519-437.
16. Klöppel G, Heitz PU, Capella C, et al. Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg. 1996;20:132-141.
17. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma: an ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15:529-553.
18. Wick MR. Neuroendocrine neoplasia: current concepts. Am J Clin Pathol. 2000;113:331-335.
19. Wick MR, Rosai J. Neuroendocrine neoplasms of the thymus. Pathol Res Pract. 1988;183:188-199.
20. nd ed. Berlin, Germany: Springer-Verlag; 2000.
21. Heitz PU, Komminoth P, Perren A. Pancreatic endocrine tumours. In: DeLellis RA, Lloyd RV, Heitz PU, et al, eds. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press; 2004:177-182.
22. Weidenmann B, Franke WW, Kuhn C, et al. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA. 1986;10:3500-3504.
23. Foley EF, Gaffey MJ, Frierson FJ Jr. The frequency and clinical significance of neuroendocrine cells within stage III adenocarcinomas of the colon. Arch Pathol Lab Med. 1998;122:912-914.
24. Grobholz R, Griebe M, Sauer CG, et al. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol. 2005;36:562-570.
25. Tischler AS. Divergent differentiation in neuroendocrine tumors of the adrenal gland. Semin Diagn Pathol. 2000;17:120-126.
26. Schmechel D, Marangos PJ, Brightman M. Neurone-specific enolase in a molecular marker for peripheral and central neuroendocrine cells. Nature. 1978;276:834-836.
27. Haimoto H, Takahashi Y, Koshikawa T, et al. Immunohistochemical localization of gamma-enolase in normal human tissues other than nervous and neuroendocrine tissues. Lab Invest. 1985;52:257-263.
28. Rode J, Dhillon AP, Doran JF, et al. PGP 9.5: a new marker for human neuroendocrine tumors. Histopathology. 1985;9:147-158.
29. Hibi K, Westra WH, Borges M, et al. PGP 9.5 as a candidate tumor marker for non-small cell lung cancer. Am J Pathol. 1999;155:711-715.
30. Lloyd RV, Wilson BS. Specific endocrine tissue marker defined by a monoclonal antibody. Science. 1983;222:628-630.
31. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134-1149.
32. Fahrenkamp AG, Wibbeke C, Winde G. Immunohistochemical distribution of chromogranins A and B secretogranin II in neuroendocrine tumors of the gastrointestinal tract. Virchows Arch. 1995;426:361-367.
33. Schmid KW, Kroll M, Hittmair A, et al. Chromogranin A and B in adenomas of the pituitary: an immunohistochemical study of 42 cases. Am J Surg Pathol. 1991;15:1072-1077.
34. Lloyd RV, Jin L, Qian X, et al. Analysis of the chromogranin A post-translation cleavage product pancreastatin and the prohormone convertases, PC2 and PC3 in normal and neoplastic human pituitaries. Am J Pathol. 1995;146:1188-1198.
35. Scopsi L, Gullo M, Rilke F, et al. Proprotein convertases (PC1/PC3 and PC2) in normal and neoplastic tissues: their use as markers of neuroendocrine differentiation. J Clin Endocrinol Metab. 1995;80:294-301.
36. Gould VE, Wiedenmann B, Lee L, et al. Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol. 1987;126:243-257.
37. Komminoth P, Roth J, Schroder S, et al. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas: implications for the differential diagnosis of adrenal gland tumors. Lab Invest. 1995;72:424-431.
38. Portela-Gomes GM, Lukinuis A, Grimeluis L. Synaptic vesicle protein 2, a new neuroendocrine cell marker. Am J Pathol. 200;157:1299-1309.
39. Shipley WR, Hammer RD, Lennington WJ, et al. Paraffin immunohistochemical detection of CD56, a useful marker for neural cell adhesion molecule in normal and neoplastic fixed tissues. Appl Immunohistochem. 1997;5:87-93.
40. Kaufmann O, Georgi T, Dietel M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol. 1997;28:1373-1378.
41. Ghali VS, Jimenez EJS, Garcia RL. Distribution of Leu 7 antigen (HNK-1) in thyroid tumors: its usefulness as a diagnostic marker for follicular and papillary carcinomas. Hum Pathol. 1992;23:21-25.
42. Fellinger EJ, Garin-Chesa P, Triche TJ, et al. Immunohistochemical analysis of Ewing's sarcoma cell surface antigen p30/32 MIC2. Am J Pathol. 1991;39:317-325.
43. Stevenson AJ, Chatten J, Bertoni F, et al. CD99 (p30/32 mic2) neuroectodermal/Ewing's sarcoma antigen as an immunohistochemical marker: review of more than 600 tumors and the literature experience. Appl Immunohistochem. 1994;2:231-240.
44. Lumadue JA, Askin FB, Perlman EJ. MIC2 analysis of small cell carcinoma. Am J Clin Pathol. 1994;102:692-694.
45. Blobel G, Gould VE, Moll R, et al. Co-expression of neuroendocrine markers and epithelial cytoskeletal proteins in bronchopulmonary neuroendocrine neoplasms. Lab Invest. 1985;52:39-51.
46. Gould VE, Moll R, Moll I, et al. Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias and neoplasias. Lab Invest. 1985;52:334-353.
47. Hoefler H, Denk H, Lackinger E, et al. Immunocytochemical demonstration of intermediate filament cytoskeleton proteins in human endocrine tissues and (neuro-) endocrine tumors. Virchows Arch A Pathol Anat Histopathol. 1986;409:609-626.
48. Miettinen M. Keratin 20: immunohistochemical marker for gastrointestinal, urothelial and Merkel cell carcinomas. Mod Pathol. 1995;8:384-388.
49. Chan JKC, Suster S, Wenig BM, et al. Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinoma and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997;21:226-234.
50. Ordonez N. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol. 2000;7:123-127.
51. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217-1223.
52. Bejarano PA, Nikiforov YE, Swenson ES, et al. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7 and cytokeratin 20 in thyroid neoplasms. Appl Immunohistochem. 2000;81:89-194.
53. Jones TD, Kernek KM, Yang XJ, et al. Thyroid transcriptionfactor-1 expression in small cell carcinoma of the urinary bladder: an immunohistochemical profile of 44 cases. Hum Pathol. 2005;36:718-723.
54. Agoff SN, Lamps LW, Phillip AT, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13:238-242.
55. Werling RW, Yaziji H, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinoma of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27:303-310.
56. Erickson LA, Papouchado B, Dimashkieh H, et al. CDX2 as a marker for neuroendocrine tumors of unknown primary sites. Endocr Pathol. 2004;15:247-252.
57. Janson ET. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors. J Endocrinol Invest. 2005;28(suppl):137-140.
58. Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocr Pathol. 2004;15:275-291.
59. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrine. 2004;80(suppl 1):51-56.
60. Papotti M, Bongiovanni M, Volante M, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461-475.
61. Nasir A, Stridsberg M, Strosberg J, et al. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006;13:52-60.